NCE-1 Intelligence & Market Opportunity

Tryptyr

Acoltremon

Ophthalmic

Ophthalmic Solution/Drops

Tryptyr is an oral neuroactive steroid modulator designed to treat dry eye disease. It acts on nervous system pathways to relieve symptoms and improve eye comfort.

Approval Date

28-May-25

NCE-1 Date

28-May-29

NCE Date

28-May-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

126

2027

218

2028

370

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Acoltremon

Innovator

ALCON LABORATORIES, INC

Dosage Form

Ophthalmic Solution/Drops

Strength

0.003%

Therapeutic Category

Ophthalmic

Usage

To treat the signs and symptoms of dry eye disease

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets